UW researchers create new low-carbon concrete with seaweed
University of Washington researchers have created a type of concrete that is more eco-friendly.
The concrete is infused with seaweed, which acts as a substance that absorbs and reduces the release of carbon dioxide.
SEATTLE - University of Washington researchers have created a new type of concrete that could cut concrete's carbon footprint.
Concrete is the second most used material by humans annually, behind water, but researchers have created seaweed-infused cement – a major component of concrete – that may emit less carbon dioxide than regular concrete.
What we know
Cement is the source of nearly 10% of all CO2 emissions worldwide, but students at UW have been addressing this problem by creating a low-carbon concrete powder infused with seaweed.
One kilogram of cement will emit almost a kilogram of CO2 in return from fossil fuels used to heat the materials and calcination, a chemical reaction during the heating of raw materials like cement.
Seaweed can combat the emissions as a carbon sink – something that absorbs more carbon than it releases – and, when mixed with concrete and made into cement, has a 21% lower global warming potential while keeping the strength of regular cement, according to the UW study.
Researchers built and used a machine-learning model to shorten the time it would take to find an ideal formula for seaweed-infused concrete. What may have taken research teams months in the past to complete, took the UW team 28 days.
Moving forward, researchers will continue to study and test how the infusion of seaweed may affect cement strength and structure, and will use machine learning to expedite the process again.
The project and research paper were co-authored by Meng-Yen Lin, a UW materials science and engineering doctoral student, Paul Grandgeorge, a former UW materials science and engineering postdoctoral researcher, and Kristen Severson, a principal researcher at Microsoft Research. The project was funded by Microsoft Research.
Learn more about the research project here.
The Source
Information in this article is from a University of Washington news release.
MORE NEWS FROM FOX 13 SEATTLE
Police dashcam video shows triple-murder suspect Travis Decker days before crime
Judge lifts gag order in Idaho murders case against Bryan Kohberger
Idaho hiker mistaken for Travis Decker tells all
Police, prosecutors disagree on charges for Renton transit shooting suspects
Grandmother shot near Pioneer Square 'thought it was a rock' that hit her
Buyer secures iconic Seattle 'Spite House' under listing price
Seattle Kraken release schedule for 2025-26 season
To get the best local news, weather and sports in Seattle for free, sign up for the daily FOX Seattle Newsletter.
Download the free FOX LOCAL app for mobile in the Apple App Store or Google Play Store for live Seattle news, top stories, weather updates and more local and national news.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer
We recently compiled a list of ImmunityBio, Inc. stands eleventh on our list. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best future stocks to buy now. It is transforming cancer care through immunotherapies that activate the body's natural defenses. Its lead therapy, ANKTIVA (nogapendekin alfa inbakicept), has already been approved by the FDA for treating certain types of bladder cancer. The company is now expanding its approach with a focus on reversing lymphopenia, an immune deficiency often caused by chemotherapy, radiation, or immunotherapy. In June 2025, the FDA authorized an Expanded Access Program for ANKTIVA under the Cancer BioShield platform, making it the first approved therapy to target treatment-induced lymphopenia in patients with solid tumors who failed standard therapies. At ASCO 2025, data showed that restoring immune health with ANKTIVA, especially when paired with CAR-NK therapy, can significantly improve survival in metastatic pancreatic cancer patients. Internationally, ImmunityBio, Inc. (NASDAQ:IBRX) is gaining momentum. In July 2025, the UK approved ANKTIVA with BCG for non-muscle invasive bladder cancer (NMIBC), marking its first approval outside the U.S. Additionally, a partnership with Saudi Arabia's health system will bring the Cancer BioShield platform to the Middle East. The company is also expanding clinical trials, including a U.S.-based study testing ANKTIVA with PD-1 inhibitors in non-small cell lung cancer (NSCLC), with plans to expand globally. Meanwhile, the business is seeking broader FDA approval for ANKTIVA + BCG in bladder cancer after addressing regulatory hurdles. A laboratory technician using high tech equipment to sequence cancer genomics. By targeting immune collapse caused by cancer treatments, ImmunityBio, Inc. (NASDAQ:IBRX) is introducing a paradigm shift, fighting both cancer and immune dysfunction simultaneously. With FDA designations, strategic global alliances, and promising clinical data, the company is advancing a potentially life-extending new standard in oncology. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Vaxcyte, Inc. (PCVX)'s VAX-24 Achieves Phase 2 Success in Infants
We recently compiled a list of Vaxcyte, Inc. stands second on our list among the best future stocks. Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotech company focused on developing next-generation pneumococcal conjugate vaccines (PCVs) to prevent invasive pneumococcal disease (IPD). The company recently reported positive topline results from its Phase 2 study of VAX-24 in infants. The 24-valent vaccine candidate met all primary endpoints for safety, tolerability, and immunogenicity compared to Pfizer's Prevnar 20, with robust immune responses and no serious vaccine-related adverse events. Full data following the fourth booster dose is expected by year-end 2025. Building on this progress, Vaxcyte, Inc. (NASDAQ:PCVX) is advancing VAX-31, a 31-valent PCV targeting broader strain coverage, approximately 94% in U.S. children and 95% in adults. The final stage of its infant Phase 2 trial is underway, with topline results expected by mid-2026. Adult Phase 3 trials are set to begin in mid-2025. VAX-31 has received FDA Breakthrough Therapy designation for adults and investigational approvals for pediatric use, highlighting its potential to address significant unmet medical needs. The business also unveiled VAX-XL, its third-generation PCV candidate offering the broadest coverage yet, signaling continued innovation in its pipeline. To support commercialization, Vaxcyte, Inc. (NASDAQ:PCVX) is constructing a manufacturing facility at Lonza, expected to be operational by early 2026. Its strong cash reserves of approximately $3 billion provide the necessary funding for R&D and scale-up. A biotechnologist in a laboratory wearing a lab coat, preparing samples for a clinical trial. Strategically, the corporation is aligning clinical, regulatory, and manufacturing efforts to become a leader in the global pneumococcal vaccine market. The recent appointment of Dr. Olivier Brandicourt, former CEO of Sanofi, to its board reinforces this vision with deep commercial expertise. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Newsweek
19 minutes ago
- Newsweek
Moon Mining Takes Giant Leap Forward With Plans to Harvest Lunar Soil
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A Seattle-based startup wants to redefine the concept of a Harvest Moon. Interlune, launched in 2020 by former Blue Origin executives, develops excavation equipment and technology to mine the moon for an extremely valuable and rare helium isotope — and already has customers lining up for the ambitious mission, including the U.S government. Extremely Valuable, Extraordinarily Rare "At $20 million dollars a kilogram, helium-3 is only resource in the universe that is priced high enough to warrant going to space and bringing it back to Earth," Interlune cofounder and CEO Rob Meyerson told Newsweek. "And we felt like with the ability to buy services, we can make the economics work and that's where we are today." If successfully extracted from lunar soil, or regolith, where Interlune estimates up to a million metric tons is concentrated, the newfound abundance of helium-3 could revolutionize a number of industries, including quantum computing, national security and medical imaging. The scarce isotope also "holds promise" as a potential fuel source for nuclear fusion, Meyerson said. A full-scale prototype of Interlune's excavator to harvest helium-3 from the moon, developed in partnership with industrial equipment manufacturer Vermeer Corporation, was unveiled by the companies in May. A full-scale prototype of Interlune's excavator to harvest helium-3 from the moon, developed in partnership with industrial equipment manufacturer Vermeer Corporation, was unveiled by the companies in May. courtesy of Interlune "We work backwards from an aspirational vision and that vision is a fleet of five harvesters that are machines that will excavate, sort, extract and separate the helium-3 from the lunar regolith and produce tens of kilograms of helium-3 per year," he said. "It's challenging and dependent on private financing. It's also dependent on a lot of other companies." Meyerson said Interlune's quest to become the first company to commercialize natural resources from space is contingent upon continued progress at Elon Musk's SpaceX, which recently unveiled the latest design of its super heavy-lift launch vehicle, Starship, ahead of preflight testing. Musk has said he hopes to utilize the spacecraft for uncrewed missions to Mars as soon as next year, though that timeline is thought to be highly optimistic. "But I do think that we need to put challenging milestones into place," Meyerson said. "And I think it's doable." While extremely rare on Earth due to its magnetic field that blocks many charged particles from the sun, helium-3 is abundant on the moon after more than 4 million years of bombardment by solar winds. A rendering of the Interlune Harvester, which will process moon dirt, or regolith, back onto the lunar surface, which will subsequently resemble a tilled field, according to company officials. A rendering of the Interlune Harvester, which will process moon dirt, or regolith, back onto the lunar surface, which will subsequently resemble a tilled field, according to company officials. courtesy of Interlune Interlune plans a prospecting mission by the end of 2027 — aiming to launch a 50-kilogram payload to sample lunar regolith in search of helium-3, Meyerson said. "And that's the mission we're working toward," he said. "Major design progress going on within the team. We're testing hardware now and getting ready to conduct our mission." Alongside partners from Vermeer Corporation, which manufactures industrial and agricultural equipment, Interlune in early May unveiled a full-scale prototype of an excavator designed to process 100 metric tons of moon dirt per hour. Since helium-3 on the lunar surface is measured in parts per billion, continuous extraction capability is essential, Meyerson said. "We're in another cycle now where we're updating the design, so we'll have more by the end of the summer or early fall," Meyerson told Newsweek of the next upcoming iteration of its excavator. Interlune envisions harvesters, a solar power plant, a rover and return launchers as key components of its multi-year mission in search of helium-3. Interlune envisions harvesters, a solar power plant, a rover and return launchers as key components of its multi-year mission in search of helium-3. courtesy of Interlune Jason Andringa, Vermeer's president and CEO, previously worked as an engineer at NASA's Jet Propulsion Laboratory, contributing to the Curiosity Rover and other early-phase mission concepts. The burgeoning collaboration with Interlune represents an opportunity for the Iowa-based firm to take its excavation expertise to an "all-new, out-of-this-world jobsite," he said. "The engineering team at Vermeer has been energized by the challenge and we are proud of the solutions we're working on in partnership with Interlune," Andringa told Newsweek in a statement. "We look forward to being a part of this impressive project that will ultimately positively impact our world for decades to come." Customers Line Up Each harvester will be about the size of an electric car, Meyerson said. Once on the lunar surface, the machines will begin a four-step proprietary process to excavate, sort, extract and separate helium-3. Meyerson acknowledged the cost of a successful helium-3 lunar mining mission will be significant, with Interlune relying on raising equity and government grants. Some contracts have already been inked, including deals with the U.S. Department of Energy Isotope Program and Maybell Quantum, a quantum infrastructure company. An artist's rendering of a rocket with a capsule containing helium-3 headed to Earth after blasting off from the lunar surface. An artist's rendering of a rocket with a capsule containing helium-3 headed to Earth after blasting off from the lunar surface. courtesy of Interlune "We have customers that have signed contracts for future sales," Meyerson told Newsweek. "Interlune still stands alone as the only company that has contracts for the sale of space resources and that's something we can use to justify our fundraising efforts going forward." Interlune, which has raised $18 million in funding to date, announced both agreements in early May while unveiling its excavator prototype. The Department of Energy has agreed to purchase three liters of helium-3 harvested from the moon no later than April 2029. Christopher Landers, director of the Department of Energy's Office of Isotope R&D and Production, said the agency works to ensure a "healthy domestic isotope ecosystem" so the United States can remain at the forefront of evolving technologies and capabilities. The agency manages federal inventories of more than 300 isotopes, including helium-3, Landers said. Interlune's leadership team, from left: chief executive officer Rob Meyerson, chief operating officer Indra Hornsby, executive chairman Harrison Schmitt, chief technology officer Gary Lai and head of product James Antifaev. Interlune's leadership team, from left: chief executive officer Rob Meyerson, chief operating officer Indra Hornsby, executive chairman Harrison Schmitt, chief technology officer Gary Lai and head of product James Antifaev. courtesy of Interlune "Helium-3 is obviously of high importance," he said. "Helium-3 is needed in cryogenics, which is a huge driver for quantum, it's needed for fusion and there's medical applications as well. But helium-3 is really, if you break it down and look at cryogenics and fusion, is on a trajectory that's moving at an exponential rate." The contract with Interlune signals the agency's attempt to facilitate a "healthy industrial availability" of helium-3, Landers said. "This was an opportunity where if Interlune is successful, they could have a major impact in making helium-3 more readily available commercially," he added. "And then similarly, through our token contract, it can establish a relationship where we could also help ensure a stable supply for that federal reserve." Maybell Quantum, which agreed to buy thousands of liters of helium-3 for delivery between 2029 and 2035, will use the extracted isotope to chill dilution refrigerators to near-absolute zero temperatures. Solar wind has bombarded the moon with helium-3 for billions of years, but Earth's magnetosphere blocks the continual stream of charged particles. The lunar surface contains more than 1 million metric tons of the rare... Solar wind has bombarded the moon with helium-3 for billions of years, but Earth's magnetosphere blocks the continual stream of charged particles. The lunar surface contains more than 1 million metric tons of the rare isotope, Interlune estimates. More courtesy of Interlune Gary Lai, Interlune's cofounder and chief technology officer, said helium-3 represents a "rare commodity" that's extremely limited on Earth yet plentiful on the moon. The company's excavator prototype is now being fine-tuned for zero-gravity operation. "It works quite well on Earth," the former chief architect at Blue Origin told Newsweek. "Now we're designing it to operate in space, and the intention is to go on our first large harvesting space mission, which we call Harvest Moon." 'Humans Find a Way' The upcoming prospecting mission will seek to prove reliable and accessible depositories of helium-3, which are most heavily concentrated in dark regions near the moon's equator. The extracted nonflammable gas must then be cooled until it liquifies before being sent in a rocket bound for Earth, Lai said. "We're actively today in our lab — like, just 100 feet behind me — doing the first sort of groundbreaking experiments to liquify and distill helium-3 out of a mixture of regular helium," Lai said. "That's a critical technology. We have to do that not only here, but we have to build the system to do that on the moon." Interlune hopes to put a full-scale excavator on the moon by 2029, potentially providing a scalable cache of helium-3 that could produce enough clean fusion energy to power the Earth for 10,000 years, as well as immediate impact in quantum computing, national security and medical imaging, Lai told Newsweek. "When there's an abundance of any material on Earth, humans find a way to use it," he said. "It has so many unique physical properties. It has many uses and I'm pretty confident that when it is more available, people will find even more uses for it because it's such a unique isotope."
